LGND - CIK 0000886163
The table below shows LIGAND PHARMACEUTICALS INC's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $115.08M | $139.38M | $67.67M | $47.99M | $63.62M | $18.14M |
| Short-term investments | $664.33M | $525.15M | $177.35M | $160.91M | $156.02M | $208.79M |
| Receivables | $53.38M | $57.56M | $41.29M | $38.49M | $34.32M | $37.48M |
| Inventory | $13.27M | $11.90M | $15.49M | $14.61M | $16.74M | $18.67M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $865.41M |
| $753.92M |
| $352.94M |
| $309.32M |
| $309.39M |
| $312.26M |
| Property, plant & equipment | $3.44M | $3.47M | $3.63M | $3.62M | $15.09M | $14.97M |
| Goodwill | $101.54M | $101.54M | $101.54M | $101.54M | $105.25M | $105.25M |
| Total assets | $1.53B | $1.48B | $948.60M | $905.43M | $954.87M | $866.40M |
| Accounts payable | $5.26M | $3.68M | $8.58M | $5.37M | $4.69M | $1.79M |
| Total current liabilities | $40.67M | $30.54M | $64.73M | $58.68M | $24.77M | $18.57M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $534.78M | $526.60M | $120.08M | $109.90M | $113.69M | $91.21M |
| Retained earnings | $594.74M | $578.22M | $461.38M | $456.53M | $530.07M | $537.24M |
| Total equity | $997.32M | $950.17M | $828.53M | $795.53M | $841.18M | $775.20M |